Development of a complete human IgG monoclonal antibody to transferrin receptor 1 targeted for adult T-cell leukemia/lymphoma

Shimosaki, Shunsuke; Nakahata, Shingo; Ichikawa, Tomonaga; Kitanaka, Akira; Kameda, Takuro; Hidaka, Tomonori; Kubuki, Yoko; Kurosawa, Gene; Zhang, Lilin; Sudo, Yukio; Shimoda, Kazuya; Morishita, Kazuhiro

doi:10.1016/j.bbrc.2017.02.039

Cited by 26 publications

(37 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus, there are some promising results of TfR-targeted drugs against different types of tumors showing strong cytotoxic effects. 37,[102][103][104] For example, Saxena et al developed a DDS of a Tf-modified cytochrome c to target TfR on A549 lung cancer cells. The results suggest that this conjugate design would be effective in cancers with enhanced expression of TfR due to its nontoxic pattern to lung normal cells.…”

Section: Transferrin (Tf) Receptormentioning

confidence: 99%

<p>Smart Targeting To Improve Cancer Therapeutics</p>

Morales‐Cruz¹,

Delgado²,

Castillo³

et al. 2019

DDDT

102

101

View full text Add to dashboard Cite

Cancer is the second largest cause of death worldwide with the number of new cancer cases predicted to grow significantly in the next decades. Biotechnology and medicine can and should work hand-in-hand to improve cancer diagnosis and treatment efficacy. However, success has been frequently limited, in particular when treating late-stage solid tumors. There still is the need to develop smart and synergistic therapeutic approaches to achieve the synthesis of strong and effective drugs and delivery systems. Much interest has been paid to the development of smart drug delivery systems (drug-loaded particles) that utilize passive targeting, active targeting, and/or stimulus responsiveness strategies. This review will summarize some main ideas about the effect of each strategy and how the combination of some or all of them has shown to be effective. After a brief introduction of current cancer therapies and their limitations, we describe the biological barriers that nanoparticles need to overcome, followed by presenting different types of drug delivery systems to improve drug accumulation in tumors. Then, we describe cancer cell membrane targets that increase cellular drug uptake through active targeting mechanisms. Stimulusresponsive targeting is also discussed by looking at the intra-and extracellular conditions for specific drug release. We include a significant amount of information summarized in tables and figures on nanoparticle-based therapeutics, PEGylated drugs, different ligands for the design of active-targeted systems, and targeting of different organs. We also discuss some still prevailing fundamental limitations of these approaches, eg, by occlusion of targeting ligands.

show abstract

Section: Transferrin (Tf) Receptormentioning

confidence: 99%

<p>Smart Targeting To Improve Cancer Therapeutics</p>

Morales‐Cruz¹,

Delgado²,

Castillo³

et al. 2019

DDDT

102

101

View full text Add to dashboard Cite

show abstract

“…Human T‐cell lymphotropic virus type 1 (HTLV‐1) causes adult T‐cell leukemia/lymphoma (ATLL), and it is shown the genes involved in iron metabolism are modulated in ATLL . Indeed, TFR1/CD71 was found to be significantly up‐regulated in ATLL, which is often associated with poor prognosis.…”

Section: Role Of Iron In Oncogenesis By Virusesmentioning

confidence: 99%

“…High expressions of IRP2 and low expression of its E3 ubiquitin ligase, FBXL5, were also reported in ATLL, which may be responsible for upregulation of TFR1 in ATLL and lead to an increase in the LIP that can support cell growth. While the expression of the heavy subunit of ferritin prominently was shown to be increased in ATLL, the level of the iron exporter, ferroportin, is significantly decreased . It has been suggested that human antihuman TFR1 monoclonal antibody can be used for treatment of ATLL patients.…”

Section: Role Of Iron In Oncogenesis By Virusesmentioning

confidence: 99%

See 1 more Smart Citation

Role of iron in cancer development by viruses

Shoja

Chenari

Jafarpour

et al. 2019

Reviews in Medical Virology

View full text Add to dashboard Cite

Increased levels of iron in body are attributed to higher cancer risk. Given the fact that 16% of all human cancers are caused by viral infections, iron is suggested to play an important role in carcinogenesis particularly those induced by viral infections. The present study provides an updated summary of the literature and the plausible mechanisms of iron involvement in cancer development by viruses. Our understanding about the interplay between viral infections and iron in different settings particularly cancer development is yet to be improved as it may shed a new light in development of new therapeutic strategies.

show abstract

“…In the last 5 years, several isolated studies have focused on additional promising drugs that inhibit ATLL cell proliferation or induce cell death by several mechanisms. Among them are chemotherapeutic molecules such as lenalidomide [ 177 ] or bortezomib [ 178 ]; plant-derived steroids, alkaloids or carotenoids [ 179 , 180 ]; pro-apoptotic molecules such as Bcl-2 (B-cell Lymphoma 2) inhibitors [ 181 , 182 ], CDK9 (Cyclin-dependent Kinase 9) inhibitor [ 183 ] or arsenic in combination with ZDV and IFN-α [ 184 ]; histone deacetylase, such as valproate; inhibitors of iron uptake such as antibodies directed against the Transferrin Receptor 1 [ 185 ]; p53 expression activator such as synthetic retinoid ST1926 [ 186 ]; or an HTLV-1-targeted gene editing zinc-finger nuclease [ 187 ].…”

Section: Htlv-1 Treatment and Drug Developmentmentioning

confidence: 99%

HTLV-1, the Other Pathogenic Yet Neglected Human Retrovirus: From Transmission to Therapeutic Treatment

Futsch

Mahieux

Dutartre

2017

Viruses

View full text Add to dashboard Cite

Going back to their discovery in the early 1980s, both the Human T-cell Leukemia virus type-1 (HTLV-1) and the Human Immunodeficiency Virus type-1 (HIV-1) greatly fascinated the virology scene, not only because they were the first human retroviruses discovered, but also because they were associated with fatal diseases in the human population. In almost four decades of scientific research, both viruses have had different fates, HTLV-1 being often upstaged by HIV-1. However, although being very close in terms of genome organization, cellular tropism, and viral replication, HIV-1 and HTLV-1 are not completely commutable in terms of treatment, especially because of the opposite fate of the cells they infect: death versus immortalization, respectively. Nowadays, the antiretroviral therapies developed to treat HIV-1 infected individuals and to limit HIV-1 spread among the human population have a poor or no effect on HTLV-1 infected individuals, and thus, do not prevent the development of HTLV-1-associated diseases, which still lack highly efficient treatments. The present review mainly focuses on the course of HTLV-1 infection, from the initial infection of the host to diseases development and associated treatments, but also investigates HIV-1/HTLV-1 co-infection events and their impact on diseases development.

show abstract

Development of a complete human IgG monoclonal antibody to transferrin receptor 1 targeted for adult T-cell leukemia/lymphoma

Cited by 26 publications

References 21 publications

<p>Smart Targeting To Improve Cancer Therapeutics</p>

<p>Smart Targeting To Improve Cancer Therapeutics</p>

Role of iron in cancer development by viruses

HTLV-1, the Other Pathogenic Yet Neglected Human Retrovirus: From Transmission to Therapeutic Treatment

Contact Info

Product

Resources

About